Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IDE397 |
Synonyms | |
Therapy Description |
IDE397 inhibits MAT2A inhibitor which may reduce synthesis of S-adenosyl-L-methionine (SAM), potentially leading to anti-tumor activity in MTAP-deficient cancers (Cancer Res 2021;81(13_Suppl):Abstract nr 1278). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IDE397 | IDE397 inhibits MAT2A inhibitor which may reduce synthesis of S-adenosyl-L-methionine (SAM), potentially leading to anti-tumor activity in MTAP-deficient cancers (Cancer Res 2021;81(13_Suppl):Abstract nr 1278). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04794699 | Phase I | IDE397 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Recruiting | USA | FRA | ESP | DEU | AUS | 2 |